Genprex
GNPX
9 hedge funds and large institutions have $2.07M invested in Genprex in 2020 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 2 closing their positions.
827% more capital invested
Capital invested by funds: $223K → $2.07M (+$1.84M)
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
200% more funds holding
Funds holding: 3 → 9 (+6)
0% less ownership
Funds ownership: 0% → 0% (-0%)
14% less call options, than puts
Call options by funds: $145K | Put options by funds: $168K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$720K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$309K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$206K |
| 4 |
Bank of New York Mellon
New York
|
+$103K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$103K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.03M |
| 2 |
Renaissance Technologies
New York
|
-$64K |
GNPX Hedge Fund Activity: Q1 2020 in Review
9 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Genprex (GNPX) for Q1 2020, worth a combined $2.07M — up 827% from $223K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new GNPX positions and 2 closed out — a net gain of 6 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $720K. The largest seller was Sabby Management, exiting entirely with an estimated $1.03M sold.
- 9 institutional investors held Genprex (GNPX) as of Q1 2020, up from 3 in Q4 2019.
- Funds reported $2.07M of Genprex stock for Q1 2020, up 827% quarter-over-quarter.
- 8 funds opened new Genprex positions in Q1 2020 and 2 closed out, a net change of +6 holders.
- The largest Genprex buyer in Q1 2020 was Vanguard Group, an estimated $720K added.
- The largest Genprex seller in Q1 2020 was Sabby Management, an estimated $1.03M sold.
Based on aggregated 13F filings for Q1 2020.